Clinical trials: Acute Myocardial Infarction With ST Segment Elevation
Acute ST-elevation Myocardial Infarction
the Effect of Prolonged Inflation Time During Stents Deployment for ST-elevation Myocardial Infarction
The purpose of this study is to determine whether prolonged inflation time on drug-eluting stents deployment for ST-elevation myocardial Infarction was better than conventional stents deployment.
- Trial name
- NCT03199014
- Testing
- deploying the Drug-eluting Stents with a prolonged time, deploying the Drug-eluting Stents with a conventional time
- Where
- China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Myocardial Infarction, ST Elevation Myocardial Infarction
10-Years Follow-up of the EXAMINATION Trial
The EXAMINATION trial was a superiority trial that compared everolimus-eluting stents (EES) versus bare-metal stents (BMS) in an all-comer ST-segment elevation myocardial infarction (STEMI) population.
- Conditions
- Myocardial Infarction, ST Elevation Myocardial Infarction, Infarction, Necrosis
- Trial name
- EXAMINAT10N (NCT04462315)
- Testing
- Everolimus Eluting Coronary Stent System, Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)
- Where
- 11 sites in Italy, Netherlands and 1 more
- Volunteers
- 1,498 people
- Sponsor
- Hospital Clinic of Barcelona
ST Segment Elevation Myocardial Infarction
DANish Study of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infarction
This study focuses on Cardioprotective strategies.
- Trial name
- DANAMI-3 (NCT01435408)
- Testing
- Conventional primary PCI, Ischemic postconditioning., Deferred stenting in primary PCI.
- Where
- 5 sites in Denmark
- Volunteers
- 2,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Acute ST-segment Elevation Myocardial Infarction
Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention
OBJECTIVE: To determine whether a therapeutic strategy involving low-dose intracoronary fibrinolytic therapy with reteplase infused after coronary reperfusion will reduce the myocardial infarction size.
- Trial name
- RECOVERII (NCT04571580)
- Testing
- Normal Saline, Reteplase Injection 9mg, Reteplase Injection 18mg
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Ge Junbo
ST-segment Elevation Myocardial Infarction (STEMI)
Fast Radial Pharmaco-invasive Strategy In ST Elevation Myocardial Infarction Trial
INTRODUCTION: The pharmaco-invasive strategy is a safe alternative to primary percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction, who cannot be in the cathlab in less than 120…
- Trial name
- FARADMI (NCT04300582)
- Testing
- Cardiac catheterization standard strategy, Cardiac catheterization fast strategy
- Where
- Brazil
- Volunteers
- 120 people
- Sponsor
- University of Sao Paulo General Hospital
ST Elevation Myocardial Infarction, Acute Coronary Syndrome
Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI
A randomized, double-blind, placebo controlled parallel group clinical trial evaluating the effects of acute treatment with a PCSK9 inhibitor (alirocumab) versus placebo on low-density lipoprotein (LDL) in 100 high-risk patients…
- Conditions
- ST Elevation Myocardial Infarction, Acute Coronary Syndrome, Hypercholesterolemia, Hyperlipidemias
- Trial name
- EPIC STEMI (NCT03718286)
- Testing
- Alirocumab
- Where
- Canada
- Volunteers
- 97 people
- Sponsor
- Population Health Research Institute
STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study
The aim of this study is to determine the prevalence of Helicobacter pylori (Hp) infection in patients with myocardial infarction (MI).
- Trial name
- HELPpilot (NCT04289012)
- Testing
- Helicobacter Pylori screening by UBT
- Where
- 2 sites in Sweden
- Volunteers
- 300 people
- Sponsor
- Karolinska Institutet
Acute ST-segment Elevation Myocardial Infarction
Effects of Glucagon Like Peptide-1 on No-reflow
The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction (STEMI).
- Trial name
- NCT02507128
- Testing
- liraglutide
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Chen Wei Ren, MD
Acute STEMI, Primary Percutaneous Coronary Arterial Intervention
Dose Reducing Door-to-balloon Time in ST-elevation Myocardial Infarction Cause Less Cost?
The investigators tried to determined whether the less D2B time led to costs savings benefited insurance payer and better outcomes to patients.
- Trial name
- NCT01545206
- Where
- Taiwan
- Volunteers
- 215 people
- Sponsor
- Far Eastern Memorial Hospital
Acute Myocardial Infarction
Thrombectomy in Acute Myocardial Infarction
The purpose of the study is to determine whether thrombus removal with aspiration thrombectomy for acute myocardial infarction reduces the infarct size.
- Trial name
- TAMI (NCT00675480)
- Testing
- Thrombectomy, Primary angioplasty
- Where
- Poland
- Volunteers
- 140 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Myocardial Infarction (MI)
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer…
- Trial name
- NCT07146360
- Testing
- Revelise (GENERIUM, Russia), Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Where
- 22 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
ST-segment Elevation Myocardial Infarction (STEMI)
Compare Early With Deferred Invasive Strategy for STEMI Presenting 24-48 Hours From Symptom Onset
The primary objective of the trial is to compare the efficacy of early with deferred invasive strategy for patients with ST-segment elevation myocardial infarction (STEMI) within 24-48h of symptom onset.
- Trial name
- NCT04575012
- Testing
- Deferred invasive strategy, Early invasive strategy
- Volunteers
- 1,200 people
- Sponsor
- Shanghai Zhongshan Hospital
Acute Myocardial Infarction
Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients
Prasugrel and ticagrelor, new P2Y12-ADP receptor antagonists, are associated with greater pharmacodynamic inhibition and reduction of cardiovascular events in patients with an acute coronary syndrome.
- Trial name
- ECCLIPSE-STEMI (NCT02929888)
- Testing
- Lysine Acetilsalicilate, Aspirin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Acute Myocardial Infarction
Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor
The aim of this study is to compare circadian variability of antiplatelet effect of prasugrel and ticagrelor maintenance doses during the initial days after acute myocardial infarction.
- Trial name
- DRAGON (NCT03454841)
- Testing
- Prasugrel, Ticagrelor
- Where
- 2 sites in Poland
- Volunteers
- 73 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Myocardial Infarction
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients…
- Trial name
- NCT00433966
- Testing
- Bivalirudin, Unfractionated heparin, Bare metal stent
- Where
- United States
- Volunteers
- 3,602 people
- Sponsor
- Cardiovascular Research Foundation, New York
Unstable Angina or Non ST Elevated Myocardial Infarction
Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers
To evaluate the impact on outcomes of the currently accepted antithrombotic strategies based on the administration of newer P2Y12 receptor blockers (prasugrel and ticagrelor) in a population of non ST elevated ACS (NSTEACS)…
- Trial name
- DUBIUS (NCT02618837)
- Testing
- Downstream strategy, Upstream strategy
- Where
- Italy
- Volunteers
- 2,520 people
- Sponsor
- University of Padova
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Myocardial Ischemia
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately…
- Trial name
- NCT00099788
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 6,560 people
- Sponsor
- Gilead Sciences
Diabetes, STEMI
Sweetheart-Register: Risk Management of Diabetics with Acute Myocardial Infarction
The Sweetheart register (Risk management of Diabetics with acute myocardial infarction) documents both the prevalence of pathologic glucose metabolism in consecutive high-risk patients with STEMI and NSTEMI in daily hospital…
- Conditions
- Diabetes, STEMI, NSTEMI, Myocardial Infarction
- Trial name
- Sweetheart (NCT01197742)
- Where
- 2 sites in Germany
- Volunteers
- 2,772 people
- Sponsor
- Stiftung Institut fuer Herzinfarktforschung
STEMI, Oxidative Stress
Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI
The investigators intend to evaluate Oxidative Stress biomarkers through a. Catalase Activity Assay; b. Lipid Peroxidation Assay; c. SOD Assay; d. Total Antioxidant Capacity Assay; e.
- Conditions
- STEMI, Oxidative Stress, Oxidative Stress Induction, Primary PCI
- Trial name
- OxiSTEMIhFABP (NCT04034940)
- Testing
- Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy